Qiagen (QGEN) was Upgraded to a Buy Rating at Kepler Capital


Kepler Capital analyst Maja Pataki upgraded Qiagen (QGEN) to Buy on November 25 and set a price target of EUR51.00. The company’s shares closed last Wednesday at $47.25.

According to TipRanks.com, Pataki is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.1% and a 26.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Siemens Healthineers AG, Koninklijke Philips, and Tecan Group AG.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Qiagen with a $57.57 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $55.27 and a one-year low of $30.23. Currently, Qiagen has an average volume of 955.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts